On the relative safety of intravenous iron formulations: New answers, new questions

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 643-644

  Chertow, Glenn M ^a   Winkelmayer, Wolfgang C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC ION;

ANAPHYLAXIS; CHEMICALLY INDUCED; DRUG HYPERSENSITIVITY; EPIDEMIOLOGY; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

ANAPHYLAXIS; DRUG HYPERSENSITIVITY; FERRIC COMPOUNDS; HEMATINICS; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956472309     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21835     Document Type: Note

References (11)

1. Wysowski et al. Am J Hematol 2010.
2. McCarthy JT, Regnier CE, Loebertmann CL, Bergstrahl EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol 2000;20:455-462.
3. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743-749. (Pubitemid 32268035)
4. Baile GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and death associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-1449.
5. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. An update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382. (Pubitemid 43159991)
6. http://www.fmcna.com/renal-pharmaceuticals.html [accessed July 15, 2010].
7. Lu M, Cohen MH, Rieves D, Pazdur R. FDA Report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010;85:315-319.
8. http://frwebgate2.access.gpo.gov/cgibin/PDFgate.cgi?WAISdocID5KrV14p/0/2/ 0&WAISaction5retrieve [accessed July 15, 2010].
9. Kaufman DW. Interpretations of associations in pharmacoepidemiology. Semin Hematol 2008;45:181-188.
10. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168:2368-2375.
11. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a re-evaluation. N Engl J Med 2010;162;189-192.